FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
Report Reveals Billions Made from Generic Drug Price Hikes
A recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit managers (PBMs) are accused of significantly inflating the cost of prescription drugs.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims
A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large ...
MedCity News16h
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
FTC bans GM from disclosing driver, consumer data to consumer reporting agencies
U.S. automaker General Motors will be banned for five years from disclosing consumers' sensitive geolocation and driver ...
FTC to ban GM from sharing connected vehicle data with consumer reporting agencies
“GM monitored and sold people’s precise geolocation data and driver behavior information, sometimes as often as every three ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
pharmaphorum1d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
FTC to sue property management company Greystar that operates in the Carolinas: Reports
Greystar is the largest property management company in the U.S. and operates thousands of properties across the Carolinas.
Snap shares drop as FTC refers MyAI chatbot complaint to the DOJ
Snap shares closed down 5% on Thursday after the Federal Trade Commission said it would refer a complaint against the company ...